36Kr reports that Akeso BioPharmaceuticals' board of directors has approved a share buyback program of up to HK$200 million. The company believes the current stock price does not reflect its intrinsic value and future prospects, making it an opportune time for the repurchase. The shares will be purchased by a trustee of the company's 2021 Restricted Share Unit Plan. AI
RANK_REASON Company announces a significant share buyback program. [lever_c_demoted from significant: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →